Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 6 | EJNMMI Radiopharmacy and Chemistry

Fig. 6

From: Au@109Pd core–shell nanoparticle conjugated to trastuzumab for the therapy of HER2+ cancers: studies on the applicability of 109Pd/109mAg in vivo generator in combined β− auger electron therapy

Fig. 6

Metabolic viability of SKOV-3 cells after treatment with different concentrations of Au@Pd-PEG and Au@Pd-PEG-trastuzumab nonradioactive conjugates (left) and radioactive doses of Au@109Pd-PEG and Au@109Pd-trastuzumab conjugates (right) after 24 h, 48 h, and 72 h of treatment.

Back to article page